Kainos Laboratories, Inc. (4556) AI Stock Analysis

• Market Cap: ¥5.24B
• Dividend Yield: 2.47%
• Average Volume (3M): 1.73K
• Price to Earnings (P/E): 8.3
• Beta (1Y): 0.23
• Revenue Growth: 5.38%
• EPS Growth: -7.04%
• Country: JP
• Employees: 133
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 43.57
• Shares Outstanding: 4,558,860
• 10 Day Avg. Volume: 2,590
• 30 Day Avg. Volume: 1,726
• PEG Ratio: -62.73
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 1.00
• P/FCF Ratio: 8.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,448.00
• Price Target Upside: 15.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 76 Outperform
• Price Target: ¥1,448.00 ▲(15.01% Upside)

Kainos Laboratories, Inc. demonstrates strong financial performance with robust revenue growth, profitability, and cash flow management, which significantly boosts its overall score. The valuation is attractive due to a low P/E ratio and a decent dividend yield. However, the technical analysis indicates a neutral trend, which slightly tempers the overall score.

Kainos Laboratories, Inc. Business Overview & Revenue Model

Company Description

Kainos Laboratories, Inc. (4556) is a biotechnology company focused on developing innovative healthcare solutions, primarily in the fields of diagnostics and therapeutics. The company specializes in the research, development, and commercialization of advanced laboratory testing technologies and medical devices that enhance patient care and improve clinical outcomes. Kainos Laboratories operates within the biotechnology sector and is dedicated to delivering high-quality, reliable products that cater to the needs of healthcare providers and patients alike.

How the Company Makes Money

Kainos Laboratories generates revenue through multiple key streams, primarily by selling its proprietary diagnostic tests and medical devices to hospitals, clinics, and laboratories. The company also engages in partnerships with pharmaceutical companies for the development of companion diagnostics, which are essential for personalized medicine. Additionally, Kainos Laboratories may earn income through research grants and collaborations with academic institutions, further expanding its product portfolio and market reach. Significant revenue is driven by the adoption of its technologies in clinical settings, alongside recurring revenue from ongoing service contracts and maintenance of diagnostic equipment.

Kainos Laboratories, Inc. Financial Statement Overview

Summary

Kainos Laboratories, Inc. is performing exceptionally well across all financial verticals. The company shows strong revenue growth and profitability, backed by excellent operational efficiency. Its balance sheet is robust with low leverage and high equity. Cash flow metrics are impressive, demonstrating effective cash management strategies. Overall, Kainos Laboratories is in a stable financial position, supporting its growth trajectory in the medical instruments and supplies industry.

Income Statement

Kainos Laboratories has demonstrated consistent revenue growth with a Revenue Growth Rate of 4.93% from 2024 to 2025. The Gross Profit Margin is 49.28% for 2025, indicating strong profitability. The Net Profit Margin has improved to 12.08%, reflecting efficient cost management. EBIT and EBITDA margins are robust at 15.52% and 17.66%, respectively, highlighting the company's operational efficiency.

Balance Sheet

The company maintains a strong financial position with a low Debt-to-Equity Ratio of 0.09, indicating conservative leverage. The Equity Ratio is high at 77.12%, showing a strong capital structure. Return on Equity (ROE) is healthy at 9.46%, reflecting effective use of equity capital to generate profits.

Cash Flow

Kainos Laboratories exhibits strong cash flow performance with a Free Cash Flow Growth Rate of 78.44% from 2024 to 2025. The Operating Cash Flow to Net Income Ratio is favorable at 1.10. The Free Cash Flow to Net Income Ratio stands at 0.99, indicating efficient conversion of earnings into free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.31B	5.06B	4.92B	4.61B	4.26B
Gross Profit	2.61B	2.55B	2.51B	2.41B	2.31B
EBITDA	936.87M	1.05B	994.26M	924.87M	763.42M
Net Income	641.02M	637.97M	568.17M	512.33M	417.40M
Balance Sheet
Total Assets	8.79B	8.59B	8.12B	7.57B	6.96B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.17B	3.02B	2.68B	2.24B
Total Debt	629.49M	862.97M	941.10M	947.61M	1.00B
Total Liabilities	2.01B	2.32B	2.45B	2.37B	2.30B
Stockholders Equity	6.78B	6.27B	5.67B	5.20B	4.66B
Cash Flow
Free Cash Flow	633.30M	354.87M	536.81M	463.19M	518.06M
Operating Cash Flow	704.78M	430.58M	544.51M	604.36M	591.25M
Investing Cash Flow	-71.30M	-72.83M	-10.33M	-141.19M	-117.16M
Financing Cash Flow	-411.04M	-203.73M	-191.14M	-31.25M	-194.61M

Kainos Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1259.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Positive. The current price of 1259 is below the 20-day moving average (MA) of 1277.10, below the 50-day MA of 1280.64, and above the 200-day MA of 1230.36, indicating a bullish trend. The MACD of -1.76 indicates Negative momentum. The RSI at 57.00 is Neutral, neither overbought nor oversold. The STOCH value of 71.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4556.

Kainos Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4556	76 Outperform	¥5.24B	8.33	―	2.47%	5.38%	-7.04%
7980	74 Outperform	¥5.56B	8.35	―	1.92%	5.45%	0.23%
7730	73 Outperform	¥147.83B	28.60	―	2.63%	5.10%	-17.80%
7979	68 Neutral	¥69.08B	16.74	―	2.72%	6.82%	-1.08%
7743	67 Neutral	¥16.68B	14.53	―	2.72%	2.38%	-48.68%
7702	54 Neutral	¥10.70B	―	―	3.88%	3.36%	-310.49%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%